GPRC5D-Targeted CAR T-Cell Therapies in Multiple Myeloma: Clinical Trial Updates and Implications of Recent Data

As a novel antigen selectively expressed on malignant plasma cells, GPRC5D has emerged as a promising therapeutic target in relapsed/refractory multiple myeloma (R/R MM). Join us for a live, expert-led webinar exploring the evolving role of GPRC5D-targeted CAR T-cell therapies in multiple myeloma. Through a review of recent clinical trial updates, including key data presented at the ASH 2025 Annual Meeting, faculty will walk you through the science, patient selection insights, and practical considerations shaping the future of GPRC5D-directed approaches. Don't miss this opportunity to stay ahead of the curve and see where these agents may fit within the evolving treatment paradigm for R/R MM.